Society for Participatory Medicine
JANUARY 27, 2022
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. My mission of advocacy was widened and deepened upon my stage IV colorectal cancer diagnosis in 2014 when I shared my expertise with others fighting for scans and treatments.
Health Populi
OCTOBER 28, 2019
patients’ negative views of the pharmaceutical industry in this study was the opioid epidemic. Over one-half of Americans blame pharmaceutical companies as most responsible for the opioid crisis, followed by physicians, whom 39% of health consumers blame, and patients, whom 38% of people blame. Exacerbating U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lloyd Price
DECEMBER 8, 2018
Craig Venter in 2014—at around $310 million, according to a Human Longevity regulatory filing obtained by Lagniappe Labs LLC, whose Prime Unicorn Index tracks valuations of privately held companies. Existing investors include biotech giant Celgene Corp. , and pharmaceutical entrepreneur Robert Duggan.
Lloyd Price
NOVEMBER 2, 2018
In October 2018, pharmaceutical giant Pfizer and private-equity firm Bain Capital LP announced the formation of Cerevel Therapeutics LLC, a drug-discovery collaboration for central nervous system disorders. Pfizer aims to invest $150 million in biotech startups focused on neurometabolic disorders, neurodegeneration, and neuroinflammation.
Lloyd Price
FEBRUARY 13, 2024
The biotech company is a spin-out of the University of Dundee and develops targeted protein degradation medicines, which have the potential to treat serious diseases that currently have limited treatments. These initiatives are helping to create a supportive environment for healthtech companies to thrive. "At
Insulin Nation
DECEMBER 18, 2013
Shire Pharmaceuticals has created Dermagraft, a similar human cell-based dressing that also has become popular for treating diabetic foot ulcers. The new price for living-cell wound therapy was part of a 700+page CMS document detailing the new pricing structure; the changed pricings are scheduled to go into effect at the beginning of 2014.
Health Populi
MAY 8, 2019
Total patient OOP costs in 2018 reached $61 billion, up $2 bn from 2017, and $5 bn from 2014. This takes us from the pharma manufacturer’s perspective to the patient’s role in the Rx ecosystem. Just under 9% of patients across all three health plan types had over $500 in OOP costs in 2018.
Expert insights. Personalized for you.
107 
Let's personalize your content